Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets

American Journal of Physiology - Cell Physiology

Volumn 274, Issue 1 43-1, 1998, Pages

  Suzuki, Masahiro ^a   Sugatani, Junko ^a   Ino, Mitsuhiro ^a   Shimura, Masahiko ^a   Akiyama, Masaki ^a   Yamazaki, Ryuta ^a   Suzuki, Yasuo ^a   Miwa, Masao ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Antagonist; Platelet activating factor; Polymorphonuclear leukocyte; Rabbit; Receptor

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; APAFANT; ISRAPAFANT; PADGEM PROTEIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; THROMBOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR BINDING; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOCYTE SHAPE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0031934454     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.1998.274.1.c47     Document Type: Article

References (31)

1. Bligh, E. G., and W. J. Dyer. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-918, 1959.
2. Braquet, P., L. Touqui, T. Y. Shen, and B. B. Vargaftig. Perspectives in platelet-activating factor research. Pharmacol. Rev. 39: 97-145, 1987.
3. Bratton, D. L., E. Dreyer, J. M. Kailey, V. A. Fadok, K. L. Clay, and P. M. Henson. The mechanism of internalization of platelet-activating factor in activated human neutrophils: enhanced transbilayer movement across the plasma membrane. J. Immunol. 148: 514-523, 1992.
4. Bruce, I. J., and R. Kerry. The effect of chloramphenicol and cycloheximide on platelet aggregation and protein synthesis. Biochem. Pharmacol. 36: 1769-1773, 1987.
5. Celi, A., G. Pellegrini, R. Lorenzet, A. D. Blasi, N. Ready, B. C. Furie, and B. Furie. P-selectin induces the expression of tissue factor on monocytes. Proc. Natl. Acad. Sci. USA 91: 8767-8771, 1994.
6. Chao, W., and M. S. Olson. Platelet-activating factor: receptors and signal transduction. Biochem. J. 292: 617-629, 1993.
7. Chilton, F. H., J. T. O'Flaherty, J. M. Ellis, C. L. Swendsen, and R. L. Wykle. Metabolic fate of platelet-activating factor in neutrophils. J. Biol. Chem. 258: 6357-6361, 1983.
8. Dittmer, J. C., and R. L. Lester. A simple, specific spray for the detection of phospholipids on thin-layer chromatograms. J. Lipid Res. 5: 126-127, 1964.
9. Grigoriadis, G., and A. G. Stewart. Albumin inhibits platelet-activating factor (PAF)-induced responses in platelets and macrophages: implications for the biologically active form of PAF. Br. J. Pharmacol. 107: 73-77, 1992.
10. Hanahan, D. J. Platelet-activating factor: a biologically active phosphoglyceride. Annu. Rev. Biochem. 55: 483-509, 1986.
11. Homma, H., A. Tokumura, and D. J. Hanahan. Binding and internalization of platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine in washed rabbit platelets. J. Biol. Chem. 262: 10582-10587, 1987.
12. Izumi, T., and T. Shimizu. Platelet-activating factor receptor: gene expression and signal transduction. Biochim. Biophys. Acta 1259: 317-333, 1995.
13. Khan, S. N., P. A. Lane, and A. D. Smith. Disaggregation of PAF-acether-aggregated platelets by verapamil and TMB-8 with reversal of phosphorylation of 40K and 20K proteins. Eur. J. Pharmacol. 107: 189-198, 1985.
14. Kramer, R. M., G. M. Patton, C. R. Pritzker, and D. Deykin. Metabolism of platelet-activating factor in human platelets: transacylase-mediated synthesis of 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. J. Biol. Chem. 259: 13316-13320, 1984.
15. Lotner, G. Z., J. M. Lynch, S. J. Betz, and P. M. Henson. Human neutrophil-derived platelet activating factor. J. Immunol. 124: 676-684, 1980.
16. Malone, B., T.-C. Lee, and F. Snyder. Inactivation of platelet activating factor by rabbit platelets: lyso-platelet activating factor as a key intermediate with phosphatidylcholine as the source of arachidonic acid in its conversion to a tetraenoic acylated product. J. Biol. Chem. 260: 1531-1534, 1985.
17. McEver, R. P., K. L. Moore, and R. D. Cummings. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J. Biol. Chem. 270: 11025-11028, 1995.
18. 14C on two-dimensional thin-layer chromatographic sheets by an ultra-high-sensitivity TV camera system. Anal. Biochem. 152: 391-395, 1986.
19. Miwa, M., T. Miyake, T. Yamanaka, J. Sugatani, Y. Suzuki, S. Sakata, Y. Araki, and M. Matsumoto. Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J. Clin. Invest. 82: 1983-1991, 1988.
20. Miwa, M., J. Sugatani, T. Ikemura, Y. Okamoto, M. Ino, K. Saito, Y. Suzuki, and M. Matsumoto. Release of newly synthesized platelet-activating factor (PAF) from human polymorphonuclear leukocytes under in vivo conditions: contribution of PAF-releasing factor in serum. J. Immunol. 148: 872-880, 1992.
21. O'Flaherty, J. T., M. C. Chabot, J. Redman, Jr., D. Jacobson, and R. L. Wykle. Receptor-independent metabolism of platelet-activating factor by myelogenous cells. FEBS Lett. 250: 341-344, 1989.
22. O'Flaherty, J. T., J. R. Redman, Jr., J. D. Schmitt, J. M. Ellis, J. R. Surles, M. H. Marx, C. Piantadosi, and R. L. Wykle. 1-O-Alkyl-2-N-methylcarbamyl-glycerophosphocholine: a biologically potent, non-metabolizable analog of platelet-activating factor. Biochem. Biophys. Res. Commun. 147: 18-24, 1987.
23. O'Flaherty, J. T., J. R. Suries, J. Redman, D. Jacobson, C. Piantadosi, and R. L. Wykle. Binding and metabolism of platelet-activating factor by human neutrophils. J. Clin. Invest. 78: 381-388, 1986.
24. Pinckard, R. N., R. S. Farr, and D. J. Hanahan. Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. J. Immunol. 123: 1847-1857, 1979.
25. Prescott, S. M., G. A. Zimmennan, and T. M. McIntyre. Platelet-activating factor. J. Biol. Chem. 265: 17381-17384, 1990.
26. Shen, T. Y., S.-B. Hwang, T. W. Doebber, and J. C. Robbins. The chemical and biological properties of PAF agonists, antagonists, and biosynthetic inhibitors. In: Platelet-Activating Factor and Related Lipid Mediators, edited by F. Snyder. New York: Plenum, 1987, p. 153-190.
27. Stafforini, D. M., T. M. McIntyre, M. E. Carter, and S. M. Prescott. Human plasma platelet-activating factor acetylhydrolase: association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem. 262: 4215-4222, 1987.
28. Stafforini, D. M., S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. Platelet-activating factor acetylhydrolase activity in human tissues and blood cells. Lipids 26: 979-985, 1991.
29. Stafforini, D. M., K. Satoh, D. L. Atkinson, L. W. Tjoelker, C. Eberhardt, H. Yoshida, T. Imaizumi, S. Takamatsu, G. A. Zimmerman, T. M. McIntyre, P. W. Gray, and S. M. Prescott. Platelet-activating factor acetylhydrolase deficiency: a missense mutation near the active site of an anti-inflammatory phospholipase. J. Clin. Invest. 97: 2784-2791, 1996.
30. Tokumura, A., T. Tsutsumi, J. Yoshida, and H. Tsukatani. Translocation of exogenous platelet-actvating factor and its lyso-compound through plasma membranes is a rate-limiting step for their metabolic conversions into alkylacylglycerophosphocholines in rabbit platelets and guinea-pig leukocytes. Biochim. Biophys. Acta 1044: 91-100, 1990.
31. Zimmerman, G. A., T. M. McIntyre, S. M. Prescott, and D. M. Stafforini. Platelet-activating factor: antagonists, terminators, molecular mimics, and microbial opportunism. J. Intern. Med. 239: 463-466, 1996.